A Prospective Trial of a Bio-absorbable Mesh in Challenging Laparoscopic Ventral or Incisional Hernia Repair
NCT ID: NCT02712398
Last Updated: 2021-01-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2016-04-30
2019-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective, Multicenter All Comers Study of Phasix Mesh for Ventral or Incisional Hernia Repair
NCT02053168
A Prospective, Multi-Center Study of Phasix™ Mesh for Ventral or Incisional Hernia Repair.
NCT01961687
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
NCT03911700
Study of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair
NCT02720042
A Prospective, Observational Study Utilizing Phasix™ Mesh During Ventral and Incisional Hernia Repair Surgery
NCT01863030
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phasix™ ST
Subjects treated with Phasix™ ST mesh
Phasix™ ST
Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Phasix™ ST
Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject must be willing to give written informed consent
* Subject must be diagnosed with ventral or abdominal incisional hernia
* Subject must be willing to undergo laparoscopic hernia repair using intraabdominal placement (with or without Component Separation Technique (CST))
* Surgeon must be able to fully close the hernia defect. Defect closure is defined as complete reapproximation of fascial edges, leaving no gap. Since the safety and effectiveness of Phasix™ ST Mesh in bridging repairs has not been evaluated or established, the defect should be closed prior to mesh use.
* Subject is expected to meet the criteria for a Class I wound
* Subjects must have 1 or more of the following pre-study conditions:
1. Body Mass Index (BMI) between 30-40 kg/m2, inclusive
2. Active smoker (including if attempts to quit smoking within two weeks of surgery have failed and the patient is still an active smoker at the time of surgery)
3. COPD presence on patient self-report
4. Diabetes mellitus (if yes, diagnosis to be confirmed via medical records or laboratory results according to 2014 Joslin Clinical Guideline for Adults with Diabetes)(Appendix 5)
5. Immunosuppression
6. Coronary Artery Disease
7. Chronic corticosteroid use: greater than 6 months systemic use
8. Serum albumin less than 3.4 g/dL
9. Advanced age: 75 years or older
10. Renal insufficiency, defined as serum creatinine concentration ≥2.5 mg/dL
Exclusion Criteria
* Subject's hernia is \> 350 cm2
* Complete removal of existing mesh from a prior hernia repair (in the same affected area) is not possible
* Subject has intact permanent mesh adjacent to the current hernia to be repaired
* Preperitoneal placement of mesh
* The subject is known to have a collagen disorder
* The subject has peritonitis
* The subject is on or suspected to be placed on chemotherapy medications during any part of the study
* The subject's Body Mass Index (BMI) is \> 40 kg/m2
* The subject has cirrhosis of the liver and/or ascites
* Subject is American Society of Anesthesiology Class 4 or 5
* Subject has a life expectancy of less than 2 years at the time of enrollment
* Subject has any condition that, in the opinion of the Investigator, would preclude the use of the study device, or preclude the subject from completing the follow-up requirements
* Subject has a surgical wound classified as Class II (Clean-Contaminated), Class III (Contaminated) or Class IV (Dirty-Contaminated)
* Subject has an active or latent systemic infection
* Patient has a contraindication to placement of mesh
* Subject requires surgical bridge repair as the sole repair
* Subject is pregnant or has plans to become pregnant during the study period
* Subject has enrolled in another interventional clinical study within the last 30 days
* Subject is part of the site personnel directly involved with this study
* Subject has a known allergy to the test device or component materials (patients with known allergies to tetracycline hydrochloride or kanamycin sulfate should be avoided).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
C. R. Bard
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William Hope, MD
Role: PRINCIPAL_INVESTIGATOR
New Hanover Regional Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale-New Haven Medical Center
New Haven, Connecticut, United States
Florida Hospital
Celebration, Florida, United States
Emory University
Atlanta, Georgia, United States
Memorial Health University Medical Center
Savannah, Georgia, United States
Via-Christi Hospital
Wichita, Kansas, United States
Georgetown Community Hospital
Georgetown, Kentucky, United States
University of Kentucky Medical Center
Lexington, Kentucky, United States
Our Lady of the Lake Regional Medical Center
Baton Rouge, Louisiana, United States
Washington University
St Louis, Missouri, United States
Methodist Hospital
Omaha, Nebraska, United States
New Hanover Regional Medical Center
Wilmington, North Carolina, United States
Legacy Emanuel Hospital
Portland, Oregon, United States
Hershey Penn State Medical Center
Hershey, Pennsylvania, United States
Carilion Clinic
Roanoke, Virginia, United States
Overlake Hospital
Bellevue, Washington, United States
University of Wisconsin
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DVL-HE-017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.